STOCK TITAN
  1. Home
  2. News
  3. AIM

AIM ImmunoTech Inc - AIM STOCK NEWS

Welcome to our dedicated news page for AIM ImmunoTech (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AIM ImmunoTech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AIM ImmunoTech's position in the market.

News
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
Rhea-AI Summary
AIM ImmunoTech Inc. has filed its Definitive Proxy Statement for the upcoming 2023 Annual Meeting of Stockholders. The company urges shareholders to vote for the Board of Directors and discard any proxy materials from the activist group. AIM has also launched www.SafeguardAIM.com to provide updates to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
none
-
News
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Rhea-AI Summary
AIM ImmunoTech Inc. announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine has been accepted for presentation at the Society for Immunotherapy of Cancer Annual Meeting. The abstract focuses on a Phase 2 trial evaluating the combination of cisplatin, Ampligen, and pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.98%
Tags
none
-
News
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs
Rhea-AI Summary
AIM ImmunoTech partners with Azenova to explore partnership opportunities for its lead asset, Ampligen®, in the treatment of solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.87%
Tags
none
News
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Rhea-AI Summary
AIM ImmunoTech Inc. announces Chris McAleer, Ph.D., to present at cancer research symposium and sponsorship of the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
conferences
-
News
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
Rhea-AI Summary
Complete topline results confirm promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66% in Phase 1 study of Ampligen for early-stage TNBC. Treatment was well-tolerated with mostly grade 1 or 2 TRAEs. Positive findings support continued development of Ampligen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.62%
Tags
none
-
News
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
AIM ImmunoTech to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements
Rhea-AI Summary
AIM Board rejects nomination by Ted D. Kellner for the 2023 Annual Meeting, citing non-compliance with Bylaws
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.25%
Tags
earnings
-
News
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
Rhea-AI Summary
AIM ImmunoTech to discuss Q2 2023 results in conference call on August 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
earnings
News
AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Rhea-AI Summary
AIM ImmunoTech completes enrollment in Phase 2 study for Ampligen as potential therapeutic for post-COVID conditions. Topline data expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
clinical trial covid-19
Stock AIM logo
AIM ImmunoTech Inc

NYSE:AIM

AIM Rankings

#5126 Ranked by Market Cap
#3581 Ranked by Stock Gains
N/A Ranked by Dividends

AIM Stock Data

24.71M
45.42M
8.99%
8.32%
0.99%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Ocala

About AIM

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as